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ABSTRACT The third E. coli and the Mucosal Immune System (ECMIS) meeting was
held at Ghent University in Belgium from 2 to 5 June 2019. It brought together an
international group of scientists interested in mechanisms of colonization, host re-
sponse, and vaccine development. ECMIS distinguishes itself from related meetings
on these enteropathogens by providing a greater emphasis on animal health and
disease and covering a broad range of pathotypes, including enterohemorrhagic, en-
teropathogenic, enterotoxigenic, enteroaggregative, and extraintestinal pathogenic
Escherichia coli. As it is well established that the genus Shigella represents a subspe-
cies of E. coli, these organisms along with related enteroinvasive E. coli are also in-
cluded. In addition, Tannerella forsythia, a periodontal pathogen, was presented as
an example of a pathogen which uses its surface glycans for mucosal interaction.
This review summarizes several highlights from the 2019 meeting and major ad-
vances to our understanding of the biology of these pathogens and their impact
on the host.
KEYWORDS ECMIS, EHEC, EIEC, ETEC, Escherichia coli, STEC, UPEC, enteric pathogens,
meeting review, zoonotic infections
The gut microbiome is a diverse community of more than 100 trillion microorgan-isms which influence mucosal and systemic immune functions via production of
metabolites and virulence factors and through interactions with other members of the
microbiota. Most bacteria in the gut belong to one of eight phyla, with the phylum
Proteobacteria accounting for ca. 2.1% of the population. Among these, the majority are
classified as Enterobacteriaceae, with Escherichia coli being by far the most abundant
species (1). A recent phylogenetic study of human-derived E. coli suggested a highly
dynamic nature with turnover on the order of months to years (2). The authors suggest,
based on data reported by Faith et al. (3), that this might also be the case for the rest
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of the microbiome. Thus, the potential for clonal turnover to change gut function is
great. Understanding how this might influence the host or how host factors affect the
microbiome is challenging.
The conference on E. coli and the Mucosal Immune System in 2019 (ECMIS-2019)
was the third conference in a series of conferences of which the first one was held in
2011, exactly 100 years after the death of Theodor Escherich. The meetings are orga-
nized to bring together basic scientists and clinicians working on E. coli and the
mucosal immune system, focusing in particular on the interaction of these intriguing
pathogens with the mucosal epithelium, and to exchange knowledge on the patho-
genicity of different types of E. coli for different species. Whereas the first meeting, in
2011, focused on differences between infections in different species, the second
meeting, in 2015, instead addressed mechanisms of different E. coli pathogens inde-
pendent of species. This third conference addressed some new insights in the inter-
actions between the host, the pathogen, and its environment and how these interac-
tions influence the host and/or pathogen. Furthermore, several examples were
presented of how this interaction can be exploited to control E. coli infections. More
information on this last conference can also be found at www.ecmis.ugent.be.
THE MUCOSAL IMMUNE SYSTEM AND MODULATION OF THE HOST BY E. COLI
The main function of the immune system is to protect the host from pathogens. The
mammalian gut harbors large numbers of diverse microbes, which establish a strong
relationship with the immune system, ensuring host homeostasis and consequently
supporting health. The microbes have strong potential to generate immunoglobulin A
(IgA), the most abundantly produced antibody isotype, which promotes maintenance
of noninvasive commensal bacteria, immune tolerance, and neutralization of invasive
pathogens through multiple mechanisms. Supporting evidence for physiologic rele-
vance comes from studies of patients with selective IgA deficiency, who exhibit an
increased susceptibility to autoimmune diseases (4). IgA synthesis occurs at different
gut-associated lymphoid tissues (GALT), either in organized tissues, such as Peyer’s
patches and mesenteric lymph nodes, or by dispersed B cells in the lamina propria in
isolated lymphoid follicles. Diversification of the IgA repertoire, primarily via T cell-
dependent pathways, is required to maintain gut homeostasis and ensure mucosal
defense. Dr. Meryem Aloulou (Center for Pathophysiology of Toulouse Purpan) began
the session “Modulation of the Host” by describing the crucial role of follicular T cells
to support B cell maturation in germinal centers (GCs), where positive and negative
regulatory roles are classically assigned to T follicular helper (Tfh) and regulatory (Tfr)
cells, respectively (5). GCs represent critical sites in which B cell responses are amplified
and refined in specificity and isotype, leading to the generation of high-affinity memory
B cells and long-lived plasma cells. Tfh cells regulate GC B cells and lead to their
maturation through somatic hypermutation (SHM) and class switch recombination
(CSR), brought about by the expression of activation-induced cytidine deaminase (AID).
Interestingly, AIDG23S mice carrying a knock-in mutation of the AID gene, which causes
specific defects in SHM, developed hyperplasia of GCs in GALTs, dysbiosis of the
microbiota, and greater susceptibility to infection, indicating that SHM is essential in
maintaining intestinal homeostasis and mucosal defense (6). GC Tfh cells are thought
to be the positive regulators of this process, while Tfr cells, a subset of Foxp3
regulatory T (Treg) cells, are negative regulators. Gut Treg cells, however, in addition to
suppressing inflammation and preserving immune tolerance, are also known to pro-
mote GC and IgA responses by generating GC T cells, ultimately resulting in the
diversification of gut microbiota (7, 8). Gut Treg depletion, in fact, causes a rapid loss
of specific IgA responses in the intestine. Overall, Tfh and Treg cells function not so
much in opposition but in a mutualistic relationship to regulate the GC reaction in the
gut, maintain a diverse and healthy gut microbiota, and foster immune homeostasis.
The exact mechanisms by which Treg and Tfh cells cooperate to achieve these
homeostatic and symbiotic functions are still poorly understood. Therefore, under-
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standing the mechanism of these processes and their regulation will facilitate the
development of new strategies for prevention or treatment of gut disorders.
Another mechanism to modulate the host immune response is used by Shigella. It
is well known that several rounds of infection with Shigella are needed to prime
antibody responses, which are of short duration. Dr. Katja Brunner (Institut Pasteur), of
the group led by Dr. Armelle Phalipon, presented research providing insights into
antibody suppression. Shigella can induce B cell death by invading the lymphocytes
and, as demonstrated with different mutants, by interaction of the type III secretion
system (T3SS) needle tip adhesin IpaD with Toll-like receptor 2 (TLR2) on B cells. For
apoptosis to occur, bacterial cosignals are required which sensitize the B cells to
apoptosis and upregulate TLR2 (9). Another mechanism was demonstrated for in
vitro-activated human blood B, CD4 T, and CD8 T lymphocytes, but also B and T
lymphocytes residing in the colonic mucosa. Shigella can inject these cells via the type
III secretion system without invading them (10). T cell activation enhances expression
of GM1 gangliosides, which interact with the O-antigen moiety of Shigella lipopolysac-
charide, making these activated T cells more susceptible to T3SS-mediated injection
(11). So far, the only outcomes of this direct targeting of activated T cells are the
impairment of CD4 T cell dynamics and migration, mediated by the T3SS effector
IpgD (12).
In the third presentation of this session, Dr. James Fleckenstein (Washington Uni-
versity School of Medicine) described new virulence factors from human enterotoxi-
genic E. coli (ETEC) strains, namely, EtpA and EatA (reviewed in reference 13). EtpA is an
extracellular adhesin, while EatA is a member of the serine protease autotransporter of
the family Enterobacteriaceae and acts as a mucinase to degrade host MUC2. This
degradation enhances epithelial access and ETEC adhesion, including EtpA-mediated
bridging of flagella with N-acetylgalactosamine (GalNAc) exposed on the surface of
epithelial cells. Affinity is highest for terminal GalNAc of blood group A, which might
explain the more severe disease in humans with this blood group (14).
Type 1 fimbriae (F1) also can play a role in ETEC interaction with the mucosa (15).
Last, an excellent example of the host-pathogen interaction mediated by ETEC heat-
labile toxin (LT) was presented. In this model, initial delivery of LT triggers upregulation
expression of CEACAM6 molecules on intestinal epithelial cells, which then serve as
critical receptors for FimH, the tip adhesin of F1. While it has been suggested that ETEC
uses toxins to propel organisms back into the environment, these studies suggest a
more sophisticated scenario wherein LT is exploited to enhance a transient epithelial
niche on small intestinal enterocytes.
MODULATION OF E. COLI BY THE HOST
It has become increasingly evident that host factors present in the gastrointestinal
tract impact virulence and growth of pathogenic bacteria. In the intestines, intrinsic
factors of different origin are sensed by invading pathogens and used to modulate
gene and protein expression. In the session “Modulation of E. coli by the Host,” Drs. Åsa
Sjöling (Karolinska Institute), Stephanie Schüller (University of East Anglia), and Guoq-
iang Zhu (Yangzhou University) presented recent data on how pathogenic E. coli
responds to different host factors.
The first talk, given by Dr. Sjöling, described the ETEC response to bile stress
encountered in the gastrointestinal tract. The bile components secreted by the gall-
bladder are reabsorbed by epithelial cells through the jejunum and ileum. Remaining bile
acids may be converted to secondary bile acids by resident microbiota, mainly in the large
intestine. Regulation of virulence and biofilm formation in response to specific concentra-
tions of bile has been reported in a number of enteropathogenic bacteria (16, 17).
Human ETEC isolates expressing the colonization factors CS5 and CS6 belong to a
globally distributed and highly virulent lineage (18). Isolates of this lineage respond
specifically to the bile salt sodium glycocholate (NaGCH), which induces specific
expression of not only colonization factor CS5 (16, 19) but also an entire regulon of
virulence factors located on a virulence plasmid as well as on the chromosome. Dr.
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Sjöling explained how this induction is governed by the transcription factor CsvR (coli
surface virulence factor regulator) located upstream of the plasmid-borne CS5 operon.
CsvR also regulates motility by downregulation of flagellar operons located on the
chromosome. Together, the results indicate that bile salt sensing induces a large
virulence regulon, controlling the initial states of attachment to the host. Oxygen
regulation is an important factor in the gut, since pathogenic species in the gastroin-
testinal (GI) tract are often facultative anaerobes that might thrive in the presence of
higher levels of oxygen. Oxygen levels decrease through the GI tract, and a radial
gradient is also present, with oxygen levels diffusing from the intestinal mucosa toward
the anaerobic gut lumen (20). Dr. Schüller described a new microaerobic diffusion
chamber system to determine the influence of oxygen and human colonic epithelium
on virulence gene expression in enteroaggregative E. coli (EAEC). While oxygen induced
expression of the transcription factor AggR and its dependent adhesion factors AAF and
dispersin, physical contact with host cells triggered subsequent expression of the
mucinase Pic and the cytotoxins HlyE and Pet. Interestingly, host cell-mediated viru-
lence gene induction occurred independently of the master regulator AggR (21, 22).
Bacteria use quorum sensing to signal a coordinated gene expression within a
bacterial population. The acyl-homoserine lactones (AHL) are produced and sensed by
Gram-negative species to communicate, and recent findings indicate that homologues
are secreted by eukaryotic cells, thereby mediating interkingdom signaling. Dr. Zhu
reported findings that exogenous and endogenously produced AHL activate acid
resistance regulons and stress responses in enterohemorrhagic E. coli (EHEC), thereby
facilitating survival in low-pH environments.
An interesting connection was revealed in this session, contrasting intestinal colo-
nization strategies used by different E. coli pathotypes. AggR and CsvR are both
members of the AraC family of transcriptional regulators and activate adherence by
distinct pathogens in response to different environmental cues. Interestingly, AggR
activates dispersin in EAEC, and CsvR (23) activates the dispersin-like protein CexE in
ETEC, as well as the putative secretion systems encoded by the aatPABCD operon.
Hence, E. coli and other enteropathogens share conserved transcription factors and
responses to host stimuli. Interestingly, both AHL and bile sensing in EHEC have
opposite effects on colonization by downregulating the locus of enterocyte effacement
(LEE) (24, 25). EHEC as well as EAEC primarily colonizes colonic epithelium, where bile
salt concentrations are lower than in the proximal small intestine, where ETEC is
preferentially found. Differences in regulatory circuits may explain the spatial prefer-
ences. In summary, increased knowledge of the most important factors sensed at the
site of infection might reveal novel targets to limit enteropathogenic disease.
MODULATION OF E. COLI BY THE ENVIRONMENT
The bacterial pathogenesis field appreciates that the study of virulence mechanisms
and gene expression needs to consider impacts of other microorganisms and metab-
olites in the environment. Enterohemorrhagic E. coli (EHEC) O157:H7 is a serious
foodborne pathogen most commonly transmitted to humans through contaminated
beef and fresh produce. Strains of O157:H7 differ in their carriage of virulence genes;
however, human disease requires the T3SS-associated gene for intimin (eae) and one or
more genes encoding Stx1 and/or Stx2, the two isoforms of Shiga toxin (Stx). A number
of publications describe mechanisms by which gut commensals regulate eae. This
session explored how the gut microbiome influences the expression and toxicity of Stx.
As Dr. Frederic Auvray (Institut de Recherche en Santé Digestive), in his talk
“Overview of Stx Phages Diversity and Their Role in Virulence and Evolution of Esche-
richia coli,” reported that genes for Stx are present within lambdoid bacteriophages.
These phages are genetically diverse and capable of jumping to other E. coli strains,
including other pathogenic variants, resulting in newly appreciated “hybrid” types.
Excision may also lead to loss of prophage from O157:H7 and other Shiga toxin-
producing E. coli (STEC) strains, which can complicate interpretation of diagnostic
assays. Induction of the phage is known to increase Stx production, and often this is
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achieved in the laboratory through addition of DNA-damaging agents such as mito-
mycin C, fluoroquinolones, or hydrogen peroxide.
Dr. Edward Dudley (The Pennsylvania State University), in the talk “Commensal E. coli
That Enhance Toxin Production by E. coli O157:H7,” described known mechanisms by
which non-O157:H7 E. coli can enhance virulence potential. This talk presented a newly
discovered mechanism (26), involving a previously unknown microcin produced by a
strain designated 0.1229. Coculture of O157:H7 with 0.1229 leads to a recA-dependent
enhancement of Stx production in vitro. Coinoculated germfree mice also exhibited
more serious signs of disease than mice inoculated with either E. coli alone. These data
demonstrate that non-Stx-producing E. coli that naturally colonize the intestines may
accelerate the course of disease.
In contrast, Dr. Mononmani Soundararajan (Institute for Molecular Infection Biology)
demonstrated that some E. coli strains dampen toxin production in the talk “Inactivation
of stx-Phages by Probiotic E. coli Strain Nissle 1917.” Nissle 1917 (EcN) is a well-established
probiotic strain and is the active component of the commercial product sold under the
name Mutaflor. This study demonstrated that incubation of EcN with an stx-converting
bacteriophage leads to a 2-log inactivation as measured by phage plaque assays. While the
exact mechanism is unclear, heat-killed EcN exhibited similar activity, while treatment with
proteinase K abolished it, suggesting that a heat-stable protein(s) is responsible. Coculture
of the laboratory strain E. coli K-12 with O157:H7 increased Stx production, and previous
work of others has shown that this mechanism involves stx-converting phage infection of
the nonpathogenic strain. This talk demonstrated that in a triculture, where O157:H7, EcN,
and K-12 are grown together, both Stx and phage levels are reduced compared to those
in the coculture lacking EcN. These data demonstrate that probiotics, including EcN, may
decrease the severity of O157:H7 disease.
Last, Dr. Anne Kijewski (Norwegian Institute of Life Sciences) provided evidence that
microbial metabolites, specifically vitamin K, may play a role in modulating virulence of
O157:H7. While vitamin K naturally occurs within the intestinal tracts of humans,
individual differences in concentration occur due to diet, host factors, and microbial
communities present. Through investigation of different chemical forms of vitamin K, it
was discovered that menadione and menadione bisulfite both inhibited the growth of
E. coli O157:H7 strain EDL933 in laboratory broth. Addition of these compounds also
decreased Stx toxin production and gene transcription and decreased stx-converting
phage levels, when bacteria were grown in the presence of hydrogen peroxide or
ciprofloxacin. This treatment also increased O157:H7 survival, collectively suggesting
that these vitamin K derivatives damp phage induction normally resulting from DNA-
damaging agents. Several DNA-damaging agents, including ciprofloxacin and mitomy-
cin C, induce cellular filamentation of O157:H7, and this phenotype was also inhibited
by menadione and menadione sodium bisulfate.
Collectively, the talks in this session provided a new appreciation of how the
intestinal environment, especially other E. coli strains, may direct the severity of disease
outcome during an O157:H7 infection. Future work is needed to understand whether
results also apply to non-O157 STEC, which is collectively a more common cause of
human illness than O157:H7. Additionally, previous studies demonstrated that extracts
from fecal bacteria can reduce Stx production, and the work presented on vitamin K
may provide us with insights into the possible mechanism(s) behind such observations.
ROLE OF BACTERIAL CELL SURFACE GLYCOPROTEINS IN COLONIZATION OF
HOST CELLS
Cell surface-associated glycosylation systems translate into a molecular barcode that
is pivotal to the pathogenicity of several bacteria, mediating distinct bacterium-host
interactions and increasing bacterial fitness in their niche (27). Thus, for an understand-
ing of the pathogenesis of bacterial infections, insight into glyco-compound biosyn-
thesis is instrumental. However, due to their secondary gene product nature, this is a
challenging endeavor (28, 29).
Dr. Christina Schäffer (BOKU University of Natural Resources and Life Sciences)
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began the session “Host-Pathogen Interaction at the Receptor Level,” presenting as an
example her work on glycobiology-based strategies of the Gram-negative anaerobe
Tannerella forsythia, which support its status as a periodontal pathogen (30). This
pathogen is gaining attention not only as a cause of periodontitis— globally the most
common inflammatory disease of bacterial origin— but also due to its link to systemic
diseases. It is covered by a two-dimensional (2D) crystalline cell surface (S) layer that
displays a unique protein glycosylation encoded by a general protein O-glycosylation
system (31, 32). The BOKU research group found that the localization of T. forsythia
within dental plaque varied depending on changes in the S-layer glycan, which also
affected aggregation with and the prevalence of other bacteria present in a multispe-
cies biofilm model (33). Immune response profiling of primary monocytes and human
oral keratinocytes (HOK) revealed that truncation of the T. forsythia glycan leads to
significant reduction of IL-1 and regulates macrophage inflammatory protein 1. HOK
infected with T. forsythia produce interleukin 1 receptor a (IL-1Ra), chemokines, and
vascular endothelial growth factor (VEGF) (34). Overall, the T. forsythia S layer and
attached sugars contribute to damping the immune response to initial infection,
mediate persistence of the bacterium in the host, and hence play a pivotal role in
orchestrating the bacterial virulence. In future studies, it will be important to deepen
our understanding of the vast array of mechanisms bacteria possess for protein
glycosylation, in order to devise novel strategies for designing vaccine formulations and
protein therapeutics, based on synthetic glycobiology approaches.
The knowledge on interaction of adhesion factors of the bacteria with host cell
glycans can also be used to develop strategies to prevent colonization. The research
group of Dr. Eric Cox (Ghent University) has demonstrated that porcine F18 ETEC
and/or Stx2e-producing F18 E. coli (STEC) interact via their fimbrial tip adhesin with
glycosphingolipids having blood group ABH determinants on a type 1 core. The relative
binding affinity for different blood group determinants decreases in the order B5 type
1 and A6 type1, A7 type I and B7 type 1, H5 type 1, A7 type 4, A8 type 1 and A9 type
1, with the latter having the weakest interaction (35). A concentration of 10 mg of the
A6 type 1 oligosaccharide per ml of PBS was able to decrease binding to intestinal villi
by 73%, suggesting that the sugar could be used as a decoy receptor to decrease
intestinal colonization. By conjugating the oligosaccharide on a carrier, the concentra-
tion needed for 70% inhibition was significantly decreased. Experiments using a small
intestinal segment perfusion model demonstrated that this was sufficient for the host
to reabsorb intestinal fluid secretion due to infections with F18 ETEC. Supplementing
feed or water of piglets with the decoy receptor significantly reduced duration and load
of fecal excretion of an F18 STEC strain, showing the potential of this strategy to
control infection in piglets.
Piglets which suckle their dams are protected against ETEC infection by milk
antibodies that interfere with binding of the fimbrial adhesins of ETEC to the mucosa,
but at weaning this protection disappears, and severe ETEC-induced diarrhea can occur.
The VIB research group (Ghent University-VIB) of Dr. Vikram Virdi demonstrated that
when the antigen-binding variable domain of the llama heavy-chain-only antibody
(VHH), which is specific for the adhesin of F4 fimbriae, was grafted onto porcine IgA
Fc and expressed in Arabidopsis seed, it was able to neutralize the infection of piglets
with an F4 ETEC strain (36). VHHs can survive harsh chemical and temperature
conditions yet remain functional. In that first study, cotransformation of VHH-IgA with
the porcine joining chain and secretory component led to the production of light-
chain-devoid, assembled multivalent dimeric, and secretory IgA-like antibodies. The
produced antibodies, a mixture of monomeric, dimeric, and secretory IgA, significantly
reduced infection.
Unexpectedly, this group demonstrated in a second study that the monomeric IgA
(mVHH-IgA) format against ETEC delivered orally in feed is sufficient to prevent ETEC
bacterial attachment and to lower the shedding of the challenge ETEC bacteria, thus
protecting piglets in a fashion similar to that of the secretory IgA (sIgA) format (37).
Furthermore, they showed that mVHH-IgAs can be produced efficiently in soybean
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seeds and a Pichia pastoris yeast cell production platform. Crushed soybean seeds
expressing mVHH-IgA, or the dried medium from Pichia secreting mVHH-IgA, when
orally delivered in a feed formulation, protected the piglets from ETEC challenge. The
convenient scalability and frugal downstream processing make these anti-ETEC mVHH-
IgAs most suitable for translation as a safe alternative prophylaxis to antibiotics.
Moreover, given the anatomical organ size similarity, the in-piglet model results are
highly relevant for translation of oral mVHH-IgA applications for human GI infections.
NEW VACCINE STRATEGIES AGAINST ETEC
Vaccination is considered an effective prevention option for ETEC-induced diarrhea.
Indeed, vaccinating pregnant livestock animals to provide protective maternal antibod-
ies to suckling newborns largely prevents neonatal diarrhea in young animals, partic-
ularly pigs (38). However, though a few vaccine candidates have undergone clinical
studies (39–41), there are still no vaccines licensed against diarrhea-causing ETEC for
humans (42, 43).
Using controlled human infection models (CHIMs) is a cost- and time-efficient way
to test new prevention strategies, including new vaccine candidates (44). Such models
already exist for ETEC disease, but there is a need for models that use relevant ETEC
strains circulating in low- and middle-income countries. Some vaccine candidates
require specific toxin or colonization factor (CF) profiles in the challenge strain; for
example, testing a heat-stable toxin (ST)-based candidate would require absence of
heat-labile toxin (LT) to avoid the contribution of LT to diarrheal stool output, the main
outcome measure in a challenge model.
Efforts to develop a model based on an epidemiologically relevant strain producing
only the human variant of ST (STh) were presented by Dr. K. Hanevik (University of
Bergen). An inoculum of 1010 CFU of the STh-only ETEC strain TW10722 was observed
to cause an overall diarrhea attack risk of 78% in healthy human volunteers (45).
However, a good immunological correlate of protection for ETEC disease is still missing
(46). While ETEC-specific small intestinal IgA antibodies are thought to be an important
contributor to protection against symptomatic ETEC infection, measuring them is both
impractical and inaccurate due to the location of infection and the dilution/contami-
nant effects of intestinal content.
The use of CHIMs has a large potential to increase understanding of ETEC patho-
physiology and the search for potential correlates of protection (44). An adequate
antibody response is dependent on CD4 T cell helper cell involvement (47). Dr.
Hanevik showed that ETEC infection elicited a rapid and long-lasting human CD4 T cell
response against the CFs CS5 and CS6 and the ETEC mucinase YghJ. These responses
correlated with serum anti-CS5 and anti-CS6 IgA levels. Further experiments should
examine which particular T cell subtypes are involved and how this correlates with
ETEC-specific IgA intestinal lavage and with protection against ETEC.
Key challenges in developing effective vaccines against ETEC diarrhea in humans
include heterogeneity among ETEC strains and difficulty in inducing robust local
mucosal immunity (42, 43). Over 25 immunologically different colonization factors (CFs)
and two very distinctive enterotoxins (STa [with two variants, STh and STp] and LT) have
been identified from ETEC strains isolated from human diarrhea patients. ETEC bacteria
producing any one or two CFs and either or both enterotoxins can cause diarrhea in
children and international travelers. To overcome these challenges, new strategies have
been implemented for developing effective ETEC vaccines (48). This includes high
expression of multiple ETEC CFs in a vaccine product, identification of conservative
antigens among ETEC strains, and application of an epitope- and structure-based
vaccinology platform to induce antibodies protecting against heterogeneous ETEC
strains. To enhance vaccine candidates in stimulating local mucosal immunity, the
mucosal adjuvants double-mutant LT (dmLT; LTR192G/L211A), LTB, CTB, and an LTB and
CTB subunit hybrid (LCTB) as well as aminopeptidase N (APN)-specific antibody formats
were applied to increase antigen uptake by small intestinal epithelial cells and thus
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local mucosal immune responses. Several of these strategies were explored in the
ECMIS-2019 symposium.
Dr. Ann-Mari Svennerholm (University of Gothenburg) presented results from sev-
eral clinical trials of an oral inactivated ETEC vaccine comprising four recombinant ETEC
strains overexpressing the most prevalent human ETEC CFs (i.e., CFA/I, CS3, CS5, and
CS6) in combination with an LCTB toxoid (ETVAX) (39, 40) and given alone or together
with dmLT adjuvant in Swedish adults and in decreasing age groups (45 years to
6 months of age) in Bangladesh. These studies showed that the vaccine is safe and
induced strong mucosal immune responses against all the primary vaccine antigens, as
determined by IgA antibody in lymphocyte secretions (ALS) and/or fecal sIgA antibody
responses in a majority of the vaccinees (39, 40). Furthermore, the vaccine was shown
to induce a mucosal immunological memory for 1 to 2 years after primary vaccination
(49). Additionally, dmLT was demonstrated to be an effective adjuvant to enhance
ETVAX in inducing mucosal immunity in Bangladeshi children. Thus, addition of dmLT
to the vaccine significantly enhanced mucosal immune responses against CFs and the
O antigen (O78 LPS) elicited by ETVAX in infants 6 to 11 months of age.
Different from the cocktail vaccine strategy, Dr. Weiping Zhang (University of Illinois)
presented the epitope- and structure-based multiepitope fusion antigen (MEFA) vac-
cinology platform to develop broadly protective ETEC subunit vaccines. A combination
of two MEFA proteins—CFA/I/II/IV MEFA, which applied the CFA/I subunit CfaB back-
bone to present neutralizing epitopes of CFA/II (CS1 to CS3) and CFA/IV (CS4 to CS6),
and the toxoid fusion MEFA 3xSTaN12S-mnLTR192G/L211A, in which three copies of the
STa toxoid STaN12S were presented by the monomeric LT mutant (a single peptide with
one LTB subunit peptide genetically fused to one LTA subunit peptide with mutations
at residues 192 and 211)—was shown to induce antibodies that broadly inhibited
adherence of ETEC bacteria producing any of the seven most important ETEC adhesins
(CFA/I and CS1 to CS6) and neutralized enterotoxicity of both toxins (LT and STa) (50).
Moreover, antibodies derived from CFA/I/II/IV MEFA and toxoid fusion protected
against ETEC diarrhea in a pig challenge model, suggesting the potential application of
these two proteins for a broadly protective multivalent ETEC subunit vaccine. Addi-
tionally, Dr. Duan from Yanzhou University reported that antibodies induced by toxoid
fusion 3xSTaN12S-mnLTR192G/L211A protein had little cross-reactivity to guanylin and
uroguanylin (51). Researchers from the Henry Jackson Foundation and the Naval
Medical Research Center examined the application of recombinant ETEC adhesin
proteins CfaEB of CFA/I and CssBA of CS6 as carrier proteins for antigens of Campylo-
bacter jejuni and Shigella flexneri and protection against ETEC adherence. From a
nonhuman primate immunization study, they reported that Aotus nancymaae monkeys
immunized with HS23/36-CfaEB were protected when challenged with ETEC and C.
jejuni. Recombinant CssBA alone was also evaluated as a vaccine against CS6 ETEC
strains. In contrast to the multivalent vaccine strategy, a conservative antigen vaccine
approach was also discussed.
Researchers also presented recent advances in inducing small intestinal mucosal
immunity. Researchers from Ghent University presented data on antibody-mediated
targeting of vaccine antigens to aminopeptidase N (also known as CD13), an apical
membrane protein in enterocytes involved in transcytosis of F4 fimbriae (52). A key
hurdle in developing oral subunit vaccines is poor transport of vaccine antigens across
the epithelial barrier (53). This might be surmounted by their targeted delivery to APN.
Upon oral administration to piglets, the selective delivery of vaccine antigens, as fused
antigens or encapsulated in microparticles, to APN by antibodies resulted in their
transport across the small intestinal barrier and the induction of antigen-specific
systemic and mucosal IgA antibody-secreting cells (54–56).
Progress on vaccines against postweaning diarrhea (PWD) in pigs was presented as
well. Coliprotec F4, an oral vaccine licensed in some European countries by Elanco
Animal Health, was shown to improve pig growth performance (based on daily weight
gain) during the first 3 weeks of the postweaning period. Pigs immunized with the oral
live bivalent E. coli F4/F18 (Coliprotec F4/F18) showed similar technical performance
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parameters and a significant reduction in medication use, compared to pigs treated
with colistin. Additionally, researchers in the United States examined the MEFA plat-
form to include neutralizing epitopes of F4 and F18 fimbriae and the toxins LT, STa, STb,
and Stx2e to develop a broadly protective vaccine against PWD (57, 58).
While developing effective vaccines against ETEC-associated diarrhea remains chal-
lenging, progress has been made in recent research. Novel vaccine technologies
include those presented at ECMIS-2019, and continuous efforts on the part of research
groups can accelerate ETEC vaccine development and potentially lead to the licensing
of effective vaccines for children’s, travelers’, and pig postweaning diarrhea.
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